TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26179482

Group type: EXPERIMENTAL
Intervention: Tofogliflozin 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofogliflozin 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofogliflozin 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofogliflozin 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofogliflozin 2.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofogliflozin (all doses)
Number of subjects: 0
Study: 23922170

Group type: EXPERIMENTAL
Intervention: High-intensity eccentric exercise (initial bout)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-intensity eccentric exercise (second bout)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control sessions (no exercise)
Number of subjects: 16
Study: 21441078

Group type: EXPERIMENTAL
Intervention: AZLI 75 mg administered 3-times daily for 28 days
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 18202030

Group type: EXPERIMENTAL
Intervention: Preoperative exercise
Number of subjects: 86

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 86
Study: 16552404

Group type: EXPERIMENTAL
Intervention: Weight-loss programme with long-chain n-3 polyunsaturated fatty acids (WLFO)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Weight-loss programme with placebo oil (WLPO)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (placebo oil, no weight-loss programme)
Number of subjects: 116
Study: 12668587

Group type: EXPERIMENTAL
Intervention: Sympathetic activity (measured by renal norepinephrine spillover)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heart failure (high sympathetic tone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pure autonomic failure (low sympathetic activity)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy aging (reduced epinephrine secretion)
Number of subjects: 0
Study: 11327291

Group type: EXPERIMENTAL
Intervention: Acute rehabilitation programme including balance and coordination training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Group I with posterior fossa tumour)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Group II with cerebellopontine angle tumour)
Number of subjects: 40
Study: 8829860

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 1905361

Group type: EXPERIMENTAL
Intervention: Minoxidil (1 ml of a 2% solution)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Nitroglycerin (2.5 gm of a 10% ointment)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 6347521

Group type: EXPERIMENTAL
Intervention: Resuscitation algorithm (protocol group)
Number of subjects: 603

Group type: COMPARATOR
Intervention: No algorithm (control group)
Number of subjects: 603
Study: 31187674

Group type: EXPERIMENTAL
Intervention: Luo Han Guo decoction (30 mL administered starting 6 hours after surgery)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group (black tea)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Luo Han Guo decoction
Number of subjects: 203
Study: 29466107

Group type: EXPERIMENTAL
Intervention: Collaborative Assessment and Management of Suicidality (CAMS)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Enhanced Care as Usual (E‐CAU)
Number of subjects: 148
Study: 25559811

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with capecitabine and cisplatin (XP)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy followed by adjuvant chemotherapy (XPRT)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Number of subjects: 458
Study: 23567482

Group type: EXPERIMENTAL
Intervention: Preventive acetaminophen (15 mg/kg IV) plus 100 mL IV normal saline
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Preemptive acetaminophen (15 mg/kg IV) plus 100 mL IV normal saline
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (100 mL IV normal saline as placebo)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Preemptive acetaminophen (15 mg/kg IV)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Preventive acetaminophen (15 mg/kg IV)
Number of subjects: 75
Study: 22207070

Group type: EXPERIMENTAL
Intervention: rESWT in spastic muscle
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: rESWT in spastic muscle + rESWT in antagonist muscle
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 19955891

Group type: EXPERIMENTAL
Intervention: Oral clonidine 3 microg/kg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (oral pantoprazole 40 mg)
Number of subjects: 66
Study: 17429784

Group type: EXPERIMENTAL
Intervention: Compact extracorporeal circulation (ECC)
Number of subjects: 0
Study: 15553551

Group type: EXPERIMENTAL
Intervention: School-based small-group education for children and home-based education for parents
Number of subjects: 44

Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 44
Study: 11245349

Group type: EXPERIMENTAL
Intervention: Aqueous oral vitamin E supplementation for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control PEM subjects
Number of subjects: 0
Study: 9575674

Group type: EXPERIMENTAL
Intervention: Intralesional injection of local anesthetic
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 1
Study: 8638785

Group type: EXPERIMENTAL
Intervention: Postoperative pain management with continuous epidural bupivacaine (S‐E group, n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group without epidural bupivacaine (S group, n = 15)
Number of subjects: 30
Study: 2405034

Group type: EXPERIMENTAL
Intervention: Commercial prebrushing mouthrinse and brushing with a dentifrice for 30 seconds
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Prebrushing water rinse and brushing with a dentifrice for 30 seconds
Number of subjects: 51

Group type: COMPARATOR
Intervention: No toothbrushing
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Commercial prebrushing mouthrinse
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Prebrushing water rinse
Number of subjects: 51
Study: 6986968

Group type: EXPERIMENTAL
Intervention: FC‐CCNU (5‐FU, Cyclophosphamide, CCNU)
Number of subjects: 47

Group type: COMPARATOR
Intervention: FC‐MTX (5‐FU, Cyclophosphamide, Methotrexate)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 47
Study: 31282555

Group type: EXPERIMENTAL
Intervention: Papworth method relaxation training
Number of subjects: 30
Study: 28253887

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (3 times per week for 5 weeks, maximum of 45 minutes walking time each)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (1-2 sessions of physiotherapy per week, hippotherapy, circuit training, and occupational therapy as necessary for 5 weeks)
Number of subjects: 0
Study: 26589253

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 444

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 444
Study: 24758776

Group type: EXPERIMENTAL
Intervention: Intraperitoneal lidocaine 50 mg/h (10 ml) once every hour
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous infusion of lidocaine 50 mg/h (10 ml) IV
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo saline 10 ml/h both intravenously and intermittently intraperitoneal
Number of subjects: 60
Study: 22717420

Group type: EXPERIMENTAL
Intervention: T80/H25 SPC (telmisartan/hydrochlorothiazide 80/25 mg)
Number of subjects: 894

Group type: COMPARATOR
Intervention: T80 (telmisartan 40 mg)
Number of subjects: 894
Study: 20151774

Group type: EXPERIMENTAL
Intervention: Exenatide 5 microg twice a day (titrated to 10 microg twice a day)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Glibenclamide 2.5 mg three times a day (titrated to 5 mg three times a day)
Number of subjects: 128
Study: 18082876

Group type: EXPERIMENTAL
Intervention: Bilingual Product Information Labels (PILs)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Old label format
Number of subjects: 225

Group type: COMPARATOR
Intervention: New label format
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Spanish only consumers with PILs
Number of subjects: 225
Study: 16230141

Group type: EXPERIMENTAL
Intervention: Intrarectal 100‐mg diclofenac suppository 1 hour before biopsy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Glycerin suppository as placebo intrarectally 1 hour before biopsy
Number of subjects: 40
Study: 12399191

Group type: EXPERIMENTAL
Intervention: HBsAg/AS04 vaccine
Number of subjects: 115

Group type: COMPARATOR
Intervention: Established hepatitis B vaccine
Number of subjects: 115
Study: 9144119

Group type: EXPERIMENTAL
Intervention: Partial whey hydrolysate formula
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Breast-feeding for > or = 4 months
Number of subjects: 216

Group type: COMPARATOR
Intervention: Conventional cow's milk formula
Number of subjects: 216

Group type: COMPARATOR
Intervention: Soy formula
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Whey hydrolysate formula
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Breast-feeding and whey hydrolysate
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Whey hydrolysate
Number of subjects: 216
Study: 8431329

Group type: EXPERIMENTAL
Intervention: alfentanil
Number of subjects: 100

Group type: COMPARATOR
Intervention: suxamethonium
Number of subjects: 100
Study: 3315604

Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 29641834

Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Combination of rACC theta marker with clinical and demographic variables
Number of subjects: 248
Study: 26822100

Group type: EXPERIMENTAL
Intervention: K305 (3% tetracaine plus 0.05% oxymetazoline)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 24880442

Group type: EXPERIMENTAL
Intervention: Anthocyanins from grapes
Number of subjects: 52

Group type: COMPARATOR
Intervention: Clobetasol propionate-neomycin-nystatin cream (CP-NN)
Number of subjects: 52
Study: 22268727

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA reconstituted with preserved saline
Number of subjects: 20

Group type: COMPARATOR
Intervention: AbobotulinumtoxinA reconstituted with preservative-free saline
Number of subjects: 20
Study: 20379742

Group type: EXPERIMENTAL
Intervention: Electronic reminder system for pathologists and education for surgeons; pathologists received inclusion criteria cards and feedback on inclusion.
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Electronic reminder system for pathologists.
Number of subjects: 266
Study: 17918748

Group type: EXPERIMENTAL
Intervention: Immunomodulation treatment
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Blocking on SFEMG
Number of subjects: 51
Study: 15855433

Group type: EXPERIMENTAL
Intervention: Brand-specific request
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: General request
Number of subjects: 152

Group type: COMPARATOR
Intervention: No request (control)
Number of subjects: 152
Study: 12486923

Group type: EXPERIMENTAL
Intervention: Early surgical removal of ICH
Number of subjects: 668

Group type: COMPARATOR
Intervention: Initial conservative management
Number of subjects: 668
Study: 10353863

Group type: EXPERIMENTAL
Intervention: Dual therapy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 32

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 32
Study: 7574449

Group type: EXPERIMENTAL
Intervention: Random Zero Method (RM)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Original Method (OM)
Number of subjects: 58
Study: 2057620

Group type: EXPERIMENTAL
Intervention: Intramuscular premedication with 0.2 mg/kg of midazolam and 0.015 mg/kg of atropine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intranasal premedication with 0.2 mg/kg of midazolam and 0.015 mg/kg of atropine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Intramuscular and Intranasal)
Number of subjects: 40
Study: 6343360

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 60
Study: 30302744

Group type: EXPERIMENTAL
Intervention: Patient navigation intervention
Number of subjects: 344
Study: 29574482

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Pelvic floor muscle training combined with intravaginal electrical stimulation (PFMT+IVES)
Number of subjects: 36
Study: 27292282

Group type: EXPERIMENTAL
Intervention: Crushed apixaban tablets in 30 mL of water
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Crushed apixaban tablets in applesauce
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Whole apixaban tablets with a high-fat, high-calorie meal
Number of subjects: 55

Group type: COMPARATOR
Intervention: Whole apixaban tablets fasted (reference)
Number of subjects: 55
Study: 24613032

Group type: EXPERIMENTAL
Intervention: Vabicaserin 200 mg/day
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Vabicaserin 400 mg/day
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Olanzapine 15 mg/day
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study: 22102736

Group type: EXPERIMENTAL
Intervention: S‐1 plus cisplatin (2 courses)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: S‐1 plus cisplatin (4 courses)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: S‐1 plus cisplatin plus docetaxel (2 courses)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: S‐1 plus cisplatin plus docetaxel (4 courses)
Number of subjects: 120
Study: 20519076

Group type: EXPERIMENTAL
Intervention: Depsides salts from salvia miltiorrhiza (DSM) 0.2 g intravenously daily for 2 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment (CT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (healthy adults)
Number of subjects: 40
Study: 17173661

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b (1.5 microg/kg/week) with ribavirin (800-1000 mg daily) for 48 weeks for genotype 1 and 4, 24 weeks for other genotypes
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b with ribavirin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 27
Study: 15792278

Group type: EXPERIMENTAL
Intervention: Recorded delivery
Number of subjects: 699

Group type: COMPARATOR
Intervention: Standard delivery
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Stamped return envelops
Number of subjects: 699

Group type: COMPARATOR
Intervention: Franked return envelops
Number of subjects: 699
Study: 12515052

Group type: EXPERIMENTAL
Intervention: DIAGNOdent (DD)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Bitewing radiographs (BW)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Visual-ranked inspection (VI)
Number of subjects: 97
Study: 9875065

Group type: EXPERIMENTAL
Intervention: Mixed diets containing different amounts and types of fibre
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citrus fibre concentrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coarse wholemeal rye bread
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fine wholemeal rye bread
Number of subjects: 0

Group type: COMPARATOR
Intervention: In vitro fermentation of mixed diets and citrus fibre concentrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: In vitro fermentation of wholemeal rye breads
Number of subjects: 0
Study: 7897074

Group type: EXPERIMENTAL
Intervention: Breast Examination Facilitation Device (BEFD) made of latex, paper, or cloth with a wedge pattern for BSE
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Breast Examination Facilitation Device (BEFD)
Number of subjects: 36
Study: 2706173

Group type: EXPERIMENTAL
Intervention: Injection at L2/3 with 3 ml of plain 0.5% bupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Injection at L4/5 with 3 ml of plain 0.5% bupivacaine
Number of subjects: 40
Study: 351355

Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine (4 mg/70 kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 g/kg)
Number of subjects: 13
Study: 31925917

Group type: EXPERIMENTAL
Intervention: Long-pulsed Nd:YAG 1064-nm laser treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topical amorolfine nail lacquer alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination treatment (laser + amorolfine)
Number of subjects: 60
Study: 30772850

Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN) intervention
Number of subjects: 152

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 152
Study: 28873425

Group type: EXPERIMENTAL
Intervention: Indoor residual spraying (IRS) with alpha cypermethrin 5WP
Number of subjects: 3089

Group type: EXPERIMENTAL
Intervention: Long lasting insecticide impregnated bed-net (LLIN)
Number of subjects: 3089

Group type: EXPERIMENTAL
Intervention: Impregnation of local bed-nets with slow release insecticide K-O TAB 1-2-3 (KOTAB)
Number of subjects: 3089

Group type: EXPERIMENTAL
Intervention: Insecticide spraying in potential breeding sites outside of house using chlorpyrifos 20EC (OUT)
Number of subjects: 3089

Group type: EXPERIMENTAL
Intervention: Combination of IRS and OUT
Number of subjects: 3089

Group type: EXPERIMENTAL
Intervention: Combination of IRS and LLIN
Number of subjects: 3089

Group type: EXPERIMENTAL
Intervention: Combination of IRS and KOTAB
Number of subjects: 3089

Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 3089
Study: 25502833

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVI) 0.5 mg with isovolemic hemodilution (IH)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Isovolemic hemodilution (IH) alone
Number of subjects: 58
Study: 21815991

Group type: EXPERIMENTAL
Intervention: Smooth neck implant
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Rough neck implant with grooves
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Scalloped rough neck with grooves
Number of subjects: 93

Group type: COMPARATOR
Intervention: Pre-implant augmentation procedure
Number of subjects: 93
Study: 21261621

Group type: EXPERIMENTAL
Intervention: DFDBA + omega‐3 polyunsaturated fatty acids + low‐dose aspirin
Number of subjects: 40

Group type: COMPARATOR
Intervention: DFDBA + placebo
Number of subjects: 40
Study: 19021072

Group type: EXPERIMENTAL
Intervention: Asian Indian adolescents
Number of subjects: 780

Group type: COMPARATOR
Intervention: Controls (Guadeloupeans not originating from India)
Number of subjects: 780
Study: 15979109

Group type: EXPERIMENTAL
Intervention: Structured or unstructured spatial arrays
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (closely matched controls)
Number of subjects: 0
Study: 12772755

Group type: EXPERIMENTAL
Intervention: Lotrafilcon A lenses
Number of subjects: 658
Study: 11106141

Group type: EXPERIMENTAL
Intervention: Gotu Kola (12-g orally administered dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9377067

Group type: EXPERIMENTAL
Intervention: Microvolume fluorimetry (MVF) method for CD34+ cell enumeration
Number of subjects: 0
Study: 8404786

Group type: EXPERIMENTAL
Intervention: Pea fibre
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Soybean fibre
Number of subjects: 6

Group type: COMPARATOR
Intervention: Low-fibre test meal (control)
Number of subjects: 6
Study: 2877708

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31892657

Group type: EXPERIMENTAL
Intervention: Brief behavioural intervention including playing Tetris
Number of subjects: 144

Group type: COMPARATOR
Intervention: Attention-placebo control group completing a brief written activity log
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Intervention group (Tetris)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (activity log)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 144
Study: 30409131

Group type: EXPERIMENTAL
Intervention: Full dose dexmedetomidine (1.0 μg/kg loading followed by 0.5 μg/kg/min infusion)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Half dose dexmedetomidine (0.5 μg/kg loading followed by 0.25 μg/kg/min infusion)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 75
Study: 26676193

Group type: EXPERIMENTAL
Intervention: 50% white vinegar
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2% sodium hypochlorite (NaOCl)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mouthrinse containing essential oils and alcohol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dishwasher use
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 60
Study: 25073447

Group type: EXPERIMENTAL
Intervention: Peer-led brief motivational intervention (BMI)
Number of subjects: 238
Study: 22266642

Group type: EXPERIMENTAL
Intervention: Weighted vest intervention (3 d·wk for 3 weeks during waking hours)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no weighted vest)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Weighted vest intervention
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study: 20818904

Group type: EXPERIMENTAL
Intervention: Neoadjuvant platinum‐based chemotherapy followed by interval debulking surgery
Number of subjects: 670

Group type: COMPARATOR
Intervention: Primary debulking surgery followed by platinum‐based chemotherapy
Number of subjects: 670